Rob Brierley
LightNews LightNews
banner
robbrierley.bsky.social
Rob Brierley
@robbrierley.bsky.social
1.3K followers 520 following 290 posts
Editor-in-Chief, The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social.

Views my own; reposting ≠ endorsement. #GastroSky #LiverSky #GISky #OncSky
Posts Replies Media Videos
Reposted by Rob Brierley
thelancet.com
What if we could find new ways to approach liver cancer prevention and treatment?

Join Helena Wang on Nov 27 to explore how we can work together to reverse the rise of this global health challenge.

👉 Register now: hubs.li/Q03GK-q50

#oncology #hepatology #lgcw2025
Blue graphic with hexagon pattern. Text says: "The Lancet Webinars. Join Helena Wang, Asia Senior Executive Editor at The Lancet, for our global webinar on global strategies to reverse the rise of liver cancer on Thursday, November 27, 2025 at 9am GMT/10am CET". A photograph of Helena Wang appears on the right-hand side. Copyright: Elsevier Ltd.
November 7, 2025 at 11:10 AM
Reposted by Rob Brierley
eclinicalmed.bsky.social
Incidence of non-colorectal/endometrial malignancies in individuals with #LynchSyndrome: a retrospective cohort study

40% of patients had non-CRC/ECs, with 11% of these cases diagnosed prior to undergoing genetic testing

www.thelancet.com/journals/ecl...
#MedSky
November 5, 2025 at 12:05 PM
Reposted by Rob Brierley
eclinicalmed.bsky.social
⭐New Series on #ChildhoodCancer in Asia now live!

Published collectively with @lancetchildadol.bsky.social, the 3 papers focus on challenges and opportunities for childhood cancer care in #Asia, which has half the global #paediatric #cancer burden

www.thelancet.com/series-do/childhood-cancer-asia
November 6, 2025 at 12:24 PM
Reposted by Rob Brierley
thelancetrheum.bsky.social
NEW RESEARCH—IgG4-related disease in the Japanese population: a whole-genome sequencing study bit.ly/4oVaGPm

Plus, linked Comment bit.ly/4hOOOmz
#Medsky #Rheumsky
November 6, 2025 at 3:42 PM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
Our December issue is out now at www.thelancet.com/journals/lan...

Content includes diet in GI disorders; IBS; IBD; oesophageal cancer; alcohol-related liver disease; MASLD + more!

#GastroSky #LiverSky #MedSky
November 6, 2025 at 6:57 AM
Reposted by Rob Brierley
thelancet.com
What if we could work together to change the future of liver cancer?

Join our webinar exploring how we can tackle the rising trend of liver cancer and differences in disease management across regions, hosted as part of London Global Cancer Week.

📆 Nov 27, 9am GMT
👉 Register: hubs.li/Q03GK-q50
Blue graphic with text saying: "The Lancet Webinars. Join our global webinar on the global strategies to reverse the rise of liver cancer on Thursday, November 27, 2025 at 9am GMT/10am CET. An image of a red liver in a blue body appears on the right of the graphic in a hexagonal frame. Copyright: Elsevier Ltd.
November 3, 2025 at 3:23 PM
Reposted by Rob Brierley
thelancet.com
Non-coeliac gluten sensitivity (NCGS) remains a highly debated condition, despite ~10% of the global population self-reporting a gluten or wheat sensitivity.

A new Review examines current evidence & provides practical guidance for assessment and management: tinyurl.com/yjafmhc5
Non-coeliac gluten sensitivity
Non-coeliac gluten sensitivity (NCGS) refers to individuals who report intestinal and extraintestinal symptoms related to the ingestion of gluten-based or wheat-based foods, in the absence of coeliac ...
www.thelancet.com
October 30, 2025 at 12:44 PM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
New research - Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial

www.thelancet.com/journals/lan...

#LiverSky #MedSky
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial
Cilofexor did not significantly reduce the rate of fibrosis progression (vs placebo) in participants with non-cirrhotic PSC. A greater percentage of cilofexor-treated participants had pruritus than pl...
www.thelancet.com
October 29, 2025 at 7:50 AM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
New research - Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

www.thelancet.com/journals/lan...

#LiverSky #MedSky
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Linerixibat significantly improved pruritus versus placebo, supporting its potential to address a major symptom of PBC. An expected increase in diarrhoea in linerixibat-treated patients was observed.
www.thelancet.com
October 29, 2025 at 7:49 AM
Reposted by Rob Brierley
thelancetoncol.bsky.social
🚨Our Nov issue is live - thelancet.com/issue/S1470-...

📊Articles: #breastcancer, #NSCLC, #prostatecancer, #melanoma

📰 Reviews: Tumour-infiltrating lymphocyte therapy in the era of genetic engineering AND AI for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO)
October 28, 2025 at 9:39 AM
Reposted by Rob Brierley
thelancetrheum.bsky.social
Attending #ACR25? Sophie Woolven, Deputy Editor, invites you to reach out with enquiries.

Explore our scope, reach & impact, commitment to publishing excellence, & more: hubs.li/Q03BLchR0 #Medsky #Rheumsky
October 24, 2025 at 3:47 PM
Reposted by Rob Brierley
lancetmicrobe.bsky.social
In advance of our November issue, our latest editorial is now online

The next decade in #AMR: getting the basics right

www.thelancet.com/journals/lan...

#IDSky #ClinMicro #OpenAccess #OA
October 27, 2025 at 10:25 AM
Reposted by Rob Brierley
eclinicalmed.bsky.social
Real-time risk prediction model for sepsis in patients with acute GI bleeds: development and validation of a monitoring tool

This validated model effectively identifies patients with AGIB at high risk of sepsis, addressing an unmet need in emergency care

www.thelancet.com/journals/ecl...
#MedSky
October 27, 2025 at 12:17 PM
Reposted by Rob Brierley
thelancet.com
How does research drive real change?

Our new Lancet- @elsfoundation.bsky.social Evidence to Impact Award is open for proposals!

If your project champions implementation science, health equity, and community engagement, apply now: tinyurl.com/j5dty567
Promotional card for the Lancet-Elsevier Foundation Evidence to Impact Award. Images depict two healthcare workers looking at a clipboard and a person facing into the sun with their eyes closed and holding their hand on their chest.
October 27, 2025 at 2:54 PM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
New research - Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study

www.thelancet.com/journals/lan...

#GastroSky #MedSky
October 28, 2025 at 7:25 AM
Reposted by Rob Brierley
thelancetrheum.bsky.social
Our November issue is live!

Including research on hip #osteoarthritis, #JIA, #BackPain, and #PsoriaticArthritis, plus much more! thelancet.com/journals/lan...
Cover by Sara Gironi Carnevale #Medsky #Rheumsky
October 21, 2025 at 4:39 PM
Reposted by Rob Brierley
thelancetrheum.bsky.social
Attending #ACR25? Sophie Woolven, Deputy Editor, invites you to reach out with enquiries.

Explore our scope, reach & impact, commitment to publishing excellence, & more: hubs.li/Q03BLchR0
Promotional card. Contact Sophie Woolven regarding content enquiries at sophie.woolven@lancet.com. Copyright: Elsevier Ltd.
October 20, 2025 at 10:36 AM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
New Review - Fatigue in people with primary biliary cholangitis: a position paper from the European Reference Network for Rare Liver Diseases

www.thelancet.com/journals/lan...

#LiverSky #MedSky
Fatigue in people with primary biliary cholangitis: a position paper from the European Reference Network for Rare Liver Diseases
Given the unmet need of fatigue in primary biliary cholangitis (PBC), the PBC working group of the European Reference Network for Rare Liver Diseases assessed and summarised the current evidence relat...
www.thelancet.com
October 17, 2025 at 7:55 AM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
New research - Thoracoscopic versus open oesophagectomy for patients with oesophageal cancer (JCOG1409 MONET): a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial

www.thelancet.com/journals/lan...

#GastroSky #MedSky #OncSky
October 16, 2025 at 5:49 AM
Reposted by Rob Brierley
thelancet.com
Alcohol use disorders remain a major public health problem globally.

A new Seminar discusses the need for integrated alcohol control policies to improve the prevention of alcohol use disorders, improve access to treatment, and reduce stigma: tinyurl.com/395uf8f5
Alcohol use disorders
Alcohol use disorders consist of conditions characterised by compulsive heavy alcohol use and loss of control over alcohol intake. Alcohol use disorders are some of the most prevalent mental disorders...
www.thelancet.com
October 15, 2025 at 11:01 AM
Reposted by Rob Brierley
thelancetendo.bsky.social
Read our November Issue, featuring glucocorticoid-induced osteoporosis, obesity, metabolic syndrome, type 2 diabetes, cardiovascular disease, type 1 diabetes, medical education, older adults, & much more tinyurl.com/mwfu4c6m

#MedSky #EndoSky #RheumSky
October 14, 2025 at 10:35 PM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
New review - Age-related changes of the gastrointestinal tract

www.thelancet.com/journals/lan...

#GastroSky #MedSky
October 14, 2025 at 6:05 AM
Reposted by Rob Brierley
thelancet.com
Most up-to-date evidence suggests several behavioural therapies are effective at treating irritable bowel syndrome (IBS), but stronger evidence is needed.

Find out more in @lancetgastrohep.bsky.social: tinyurl.com/2r4hvz3x
Efficacy of behavioural therapies for irritable bowel syndrome: a systematic review and network meta-analysis
Several behavioural therapies are efficacious for global symptoms in IBS, although the most evidence exists for those classed as brain–gut behaviour therapies. However, certainty in the evidence for a...
www.thelancet.com
October 13, 2025 at 3:14 PM
Reposted by Rob Brierley
lancetrh-americ.bsky.social
The October 2025 issue of The Lancet Regional Health - Americas is now available online: lnkd.in/gn2YTxQW
In this issue, we covered #Malaria; #ColorectalCancer; #ChagasDisease; #CognitiveHealth; #TobaccoPolicy; #SickleCell; #ObesityDiagnosis; #HealthCareResilience; and much more.
October 13, 2025 at 4:06 PM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
New research - Efficacy of behavioural therapies for irritable bowel syndrome: a systematic review and network meta-analysis

www.thelancet.com/journals/lan...

#GastroSky #MedSky @alexanderford25.bsky.social @romegastropsych.bsky.social
Efficacy of behavioural therapies for irritable bowel syndrome: a systematic review and network meta-analysis
Several behavioural therapies are efficacious for global symptoms in IBS, although the most evidence exists for those classed as brain–gut behaviour therapies. However, certainty in the evidence for a...
www.thelancet.com
October 10, 2025 at 11:47 AM